Cargando…
AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy
Mutations in the GJB1 gene, encoding the gap junction (GJ) protein connexin32 (Cx32), cause X-linked Charcot-Marie-Tooth disease (CMT1X), an inherited demyelinating neuropathy. We developed a gene therapy approach for CMT1X using an AAV9 vector to deliver the GJB1/Cx32 gene under the myelin protein...
Autores principales: | Kagiava, Alexia, Karaiskos, Christos, Richter, Jan, Tryfonos, Christina, Jennings, Matthew J., Heslegrave, Amanda J., Sargiannidou, Irene, Stavrou, Marina, Zetterberg, Henrik, Reilly, Mary M., Christodoulou, Christina, Horvath, Rita, Kleopa, Kleopas A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599011/ https://www.ncbi.nlm.nih.gov/pubmed/33692503 http://dx.doi.org/10.1038/s41434-021-00250-0 |
Ejemplares similares
-
Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy
por: Kagiava, Alexia, et al.
Publicado: (2023) -
Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies
por: Stavrou, Marina, et al.
Publicado: (2021) -
Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery
por: Kagiava, A., et al.
Publicado: (2021) -
Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy
por: Schiza, Natasa, et al.
Publicado: (2019) -
A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice
por: Stavrou, Marina, et al.
Publicado: (2022)